法国一项前瞻性描述性1年研究:所有非肌层浸润性膀胱癌的卡介苗治疗发放情况
该研究在2021年2月至2022年2月法国卡介苗国家配额期间,通过法国国家药品安全局要求 distributor MEDAC 收集所有卡介苗处方数据,描述非肌层浸润性膀胱癌的临床病理特征及辅助治疗指征。共收到25878份请求,涉及19024例患者,其中60.5%年龄≥70岁;诱导治疗12704份(49.1%),维持治疗13174份(50.9%)。维持治疗组高危非肌层浸润性膀胱癌比例更高(91.7% vs 90.2%,P<0.0001)。作者认为参考流行病学研究低估了高复发和进展风险非肌层浸润性膀胱癌的发病率。
要点
- 配额1年内共25878份卡介苗请求,涉及19024例患者,60.5%年龄≥70岁。
- 诱导治疗请求12704份(49.1%),维持治疗请求13174份(50.9%)。
- 维持治疗组高危非肌层浸润性膀胱癌比例高于诱导组(91.7% vs 90.2%,P<0.0001)。
核心结论
- 作者认为,参考流行病学研究低估了高复发和进展风险非肌层浸润性膀胱癌的发病率。
- 作者认为这些结果有助于更好地确定未来护理需求。
研究设计与样本
- 前瞻性描述性1年研究,于2021年2月至2022年2月在法国本土开展。
- 法国国家药品安全局要求法国泌尿外科学会提出基于临床评分的卡介苗科学配额方案,并要求 distributor MEDAC 收集所有卡介苗请求的评分并优先处理高分患者。
- 对每份膀胱内卡介苗处方记录肿瘤分期、分级、大小、数量、复发时间、原位癌、年龄、替代治疗可及性及卡介苗治疗进度。
- 对配额年收集的数据进行描述性分析。
主要发现
- 配额1年内共提出25878份卡介苗请求,涉及19024例患者,其中60.5%年龄≥70岁。
- 诱导治疗请求12704份(49.1%),维持治疗请求13174份(50.9%)。
- 接受维持治疗的NMIBC中高危NMIBC比例高于请求诱导治疗的NMIBC(91.7% vs 90.2%,P<0.0001)。
- 法国本土1年内因NMIBC接受卡介苗辅助治疗的病例数估计为12704例/66062188名居民。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the clinico-pathological characteristics of non-muscle-invasive bladder cancer (NMIBC) treated in metropolitan France over 1 year when bacille Calmette-Guérin (BCG) was subject to a national quota, and to document, in the context of recurrent shortages of intravesical BCG for NMIBC, the real-life indications for adjuvant treatment. MATERIALS AND METHODS: Between February 2021 and February 2022, the French National Agency for the Safety of Medicines (ANSM) asked the French Association of Urology to propose a science-based quota solution for BCG using a clinical score. The ANSM then asked the distributor of the drug, MEDAC, to collect the scores for all patients for whom BCG was requested by healthcare institutions and to prioritize the requests for patients with the highest scores. Tumour stage, grade, size, number, time to recurrence, carcinoma in situ, age, accessibility of alternative treatments (total cystectomy, radio-chemotherapy, thermo-chemotherapy) and BCG treatment progress (initiation or maintenance) were documented for each intravesical BCG prescription. A descriptive analysis of the data collected during the quota year was performed. RESULTS: During the 1-year quota, 25 878 requests for BCG were made for 19 024 patients, 60.5% of whom were aged ≥70 years. Requests for induction and maintenance treatment accounted for 12 704 (49.1%) and 13 174 prescriptions (50.9%), respectively. NMIBC treated with BCG maintenance therapy was more frequently high-risk NMIBC (91.7% vs 90.2%; P < 0.0001) than NMIBC for which induction therapy was requested. The number of cases of NMIBC leading to BCG adjuvant treatment was estimated at 12 704 cases/66 062 188 inhabitants over 1 year in metropolitan France. CONCLUSIONS: Our data suggest that the incidence of NMIBC at high risk of recurrence and progression is underestimated in reference epidemiological studies. These results should help to better define future care needs.
引用
- Neuzillet Y, Leon P, Seisen T, et al. A prospective descriptive 1-year study in France of all BCG therapy dispensations for non-muscle-invasive bladder cancer. BJU Int. 2022. PMID: 36462164. doi:10.1111/bju.15941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。